↓ Skip to main content

A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): A review of clinical studies on weight loss and glycemic control

Overview of attention for article published in Nutrition Journal, March 2011
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)

Mentioned by

news
3 news outlets
blogs
4 blogs
twitter
27 tweeters
facebook
7 Facebook pages
video
2 video uploaders

Citations

dimensions_citation
142 Dimensions

Readers on

mendeley
367 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): A review of clinical studies on weight loss and glycemic control
Published in
Nutrition Journal, March 2011
DOI 10.1186/1475-2891-10-24
Pubmed ID
Authors

Marilyn L Barrett, Jay K Udani

Abstract

Obesity, and resultant health hazards which include diabetes, cardiovascular disease and metabolic syndrome, are worldwide medical problems. Control of diet and exercise are cornerstones of the management of excess weight. Foods with a low glycemic index may reduce the risk of diabetes and heart disease as well as their complications. As an alternative to a low glycemic index diet, there is a growing body of research into products that slow the absorption of carbohydrates through the inhibition of enzymes responsible for their digestion. These products include alpha-amylase and glucosidase inhibitors. The common white bean (Phaseolus vulgaris) produces an alpha-amylase inhibitor, which has been characterized and tested in numerous clinical studies. A specific and proprietary product named Phase 2® Carb Controller (Pharmachem Laboratories, Kearny, NJ) has demonstrated the ability to cause weight loss with doses of 500 to 3000 mg per day, in either a single dose or in divided doses. Clinical studies also show that Phase 2 has the ability to reduce the post-prandial spike in blood glucose levels. Experiments conducted incorporating Phase 2 into food and beverage products have found that it can be integrated into various products without losing activity or altering the appearance, texture or taste of the food. There have been no serious side effects reported following consumption of Phase 2. Gastro-intestinal side effects are rare and diminish upon extended use of the product. In summary, Phase 2 has the potential to induce weight loss and reduce spikes in blood sugar caused by carbohydrates through its alpha-amylase inhibiting activity.

Twitter Demographics

The data shown below were collected from the profiles of 27 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 367 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 5 1%
Canada 2 <1%
Mexico 2 <1%
Indonesia 1 <1%
Czechia 1 <1%
India 1 <1%
United States 1 <1%
Unknown 354 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 77 21%
Student > Master 56 15%
Researcher 50 14%
Student > Ph. D. Student 49 13%
Student > Postgraduate 23 6%
Other 61 17%
Unknown 51 14%
Readers by discipline Count As %
Agricultural and Biological Sciences 99 27%
Medicine and Dentistry 52 14%
Biochemistry, Genetics and Molecular Biology 37 10%
Chemistry 35 10%
Pharmacology, Toxicology and Pharmaceutical Science 21 6%
Other 57 16%
Unknown 66 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 78. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 September 2021.
All research outputs
#359,740
of 18,954,860 outputs
Outputs from Nutrition Journal
#112
of 1,341 outputs
Outputs of similar age
#2,607
of 232,249 outputs
Outputs of similar age from Nutrition Journal
#1
of 1 outputs
Altmetric has tracked 18,954,860 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,341 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.9. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 232,249 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them